NCT06532058: Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 2 | 53 | RoW | QHRD107 capsule,Venclexta and Azacitidine, CDK9 inhibitors | Changzhou Qianhong Bio-pharma Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) | 02/25 | 05/25 | | |